SCHEMBL1027989

SCHEMBL1027989

C=C(C)C(=O)NCOc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.51
MTNR1B P49286 5/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GPR174 Q9BXC1 1/20 0.44
ALOX15 P16050 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 3/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 1/20 0.42
THRB P10828 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
PTPN1 P18031 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698008 0.83 MTNR1A (0.71) MTNR1AMTNR1BL3MBTL1KDM4EALDH1A1
SCHEMBL19617577 0.82 L3MBTL1 (0.71) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL6691222 0.82 MTNR1A (0.68) MTNR1AMTNR1BL3MBTL1ALOX15RECQL
SCHEMBL10362456 0.81 L3MBTL1 (0.65) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL24756165 0.81 MAPT (0.58) L3MBTL1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL10364020 0.80 L3MBTL1 (0.63) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL10362652 0.80 L3MBTL1 (0.63) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL10362391 0.80 L3MBTL1 (0.63) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL10362325 0.80 L3MBTL1 (0.63) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL
SCHEMBL10362350 0.80 L3MBTL1 (0.63) MTNR1AMTNR1BL3MBTL1ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230205087-A1 PHOTORESIST UNDERLAYER COMPOSITION DUPONT SPECIALTY MATERIALS KOREA LTD (KR) 2023-06-29 US disclosed
US-20210129184-A1 BRILLIANT PIGMENT-CONTAINING AQUEOUS BASE COAT COATING MATERIAL, AND METHOD FOR FORMING MULTILAYER FILM USING SAME KANSAI PAINT CO., LTD. (JP) 2021-05-06 US disclosed
US-20190039090-A1 BRILLIANT PIGMENT-CONTAINING AQUEOUS BASE COAT COATING MATERIAL, AND METHOD FOR FORMING MULTILAYER FILM USING SAME KANSAI PAINT CO., LTD. (JP) 2019-02-07 US disclosed
EP-2620444-B1 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORP (JP) 2015-05-06 EP disclosed
US-8835656-B2 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORPORATION (JP) 2014-09-16 US disclosed
US-8669356-B2 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORPORATION (JP) 2014-03-11 US disclosed
US-8592542-B2 Porous resin beads and method of producing nucleic acid using the same NITTO DENKO CORPORATION (JP) 2013-11-26 US disclosed
US-20130197117-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2013-08-01 US disclosed
EP-2620444-A1 Linker and Support for Solid Phase Synthesis of Nucleic Acid Nitto Denko Corporation (JP) 2013-07-31 EP disclosed
EP-2357188-A1 Linker and support for solid phase synthesis of nucleic acid Nitto Denko Corporation (JP) 2011-08-17 EP disclosed
US-20110092690-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID NITTO DENKO CORPORATION (JP) 2011-04-21 US disclosed
EP-2138519-B1 Porous resin beads and method of producing nucleic acid using the same NITTO DENKO CORP (JP) 2011-01-19 EP disclosed
US-20090326210-A1 POROUS RESIN BEADS AND METHOD OF PRODUCING NUCLEIC ACID USING THE SAME NITTO DENKO CORPORATION (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326210-A1 POROUS RESIN BEADS AND METHOD OF PRODUCING NUCLEIC ACID USING THE SAME PCNA, ARID2, PHAX MTNR1A 4068/4885MTNR1B 3994/4885L3MBTL1 3828/4885
US-20110092690-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID RNGTT, NSUN2, SSU72 MTNR1A 4314/4885MTNR1B 4673/4885L3MBTL1 765/4885
US-20130197117-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID SSU72, NSUN2, RNGTT MTNR1A 4266/4885MTNR1B 4672/4885L3MBTL1 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.